| 0.303 -0.003 (-1.05%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.49 | 1-year : | 0.59 |
| Resists | First : | 0.42 | Second : | 0.5 |
| Pivot price | 0.39 |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.39 |
| MA(100) : | 0.46 |
MA(250) : | 0.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.3  |
D(3) : | 5.3 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 2.13 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BMRA ] has closed above bottom band by 14.2%. Bollinger Bands are 44.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.32 - 0.32 | 0.32 - 0.32 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.3 - 0.3 | 0.3 - 0.31 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Wed, 04 Sep 2024
Saudi Arabia approves Biomerica's prostate cancer test - Investing.com
Fri, 28 Jun 2024
Biomerica Chairman Jack Kenny steps down - Investing.com
Wed, 20 Dec 2023
Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Tue, 11 May 2021
MedTech Round Up: Update On Products By Biomerica, 908 Devices, Ekso Bionics, Hologic - Yahoo Finance
Sun, 14 Feb 2021
Biomerica (NASDAQ:BMRA) Stock Quotes, Forecast and News Summary - Benzinga
Tue, 08 Sep 2020
BMRA - BIOMERICA INC Latest Stock News & Market Updates - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 17 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 17.6 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 84 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | -117.5 % |
| Operating Margin | -196.7 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | -92.1 % |
| Qtrly Rev. Growth | -8.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.32 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.85 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0.94 |
| Price to Cash Flow | -0.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|